Ibrutinib Market to Reach USD 62 Billion by 2030, Driven by Growing Cancer Prevalence and Advancements in Oncology Treatments

Ibrutinib Market to Reach USD 62 Billion by 2030, Driven by Growing Cancer Prevalence and Advancements in Oncology Treatments

According to Next Move Strategy Consulting, the global Ibrutinib Market, is expected to experience a remarkable growth, reaching USD 62 billion by 2030. With a robust compound annual growth rate (CAGR) of 23% by 2030, the market is driven by the rising incidence of blood cancers, continuous advancements in healthcare infrastructure, and the increasing development of generic cancer drugs.

Ibrutinib, marketed under the brand name Imbruvica, is a kinase inhibitor used to treat various blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom’s macroglobulinemia, and as a second-line treatment for marginal zone lymphoma and chronic graft-versus-host disease. The drug works by blocking abnormal proteins that contribute to the spread of cancer cells.

Download Free Sample: https://www.nextmsc.com/ibrutinib-market/request-sample

Market Dynamics

The increasing number of cancer patients globally is a key factor propelling the demand for Ibrutinib. In particular, the rising prevalence of leukemia, lymphoma, and myeloma is expected to significantly boost the market. For instance, the American Cancer Society reported in 2022 that approximately 60,650 new cases of leukemia were diagnosed in the U.S., with 24,000 fatalities.

Furthermore, major pharmaceutical companies, including Johnson & Johnson, Pfizer, and Bluepharma, are developing generic drugs to treat cancer, contributing to market expansion. A notable example is Johnson & Johnson’s submission to the European Medicines Agency in March 2022 for the approval of a new indication for IMBRUVICA in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma.

Additionally, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Commission (EC) are playing a crucial role in the approval of innovative cancer drugs, including ibrutinib. For instance, Zydus Cadila received FDA approval in April 2021 for the use of their Ibrutinib Capsules, expanding treatment options for cancer patients.

However, side effects such as high blood pressure and diarrhea associated with ibrutinib may present challenges to the market. Nevertheless, ongoing research into immunotherapy and radiotherapy is expected to open new opportunities for market growth by enhancing the efficacy of ibrutinib and other cancer treatments.

Inquire Before Buying: https://www.nextmsc.com/ibrutinib-market/inquire-before-buying

Market Segmentation

The ibrutinib market is segmented based on product type, application, and geography:

  • By Product Type: 140 mg, 10 mg, and 5 mg
  • By Application: Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Follicular Lymphoma (FL)
  • By Geography: North America, Europe, Asia-Pacific, and Rest of the World (RoW)

Geographical Analysis

North America currently dominates the ibrutinib market and is expected to maintain its leadership during the forecast period. Factors such as the rising incidence of colon, rectum, and stomach cancers, along with significant R&D investments in oncology, are driving the growth of the market in this region. In 2020, the GLOBOCAN report identified over 101,000 cases of colon cancer and 44,000 cases of rectal cancer in the U.S. alone.

The Asia-Pacific region is also witnessing steady market growth due to an increasing geriatric population and expanding healthcare infrastructure in countries such as China, Japan, and India. Additionally, the rising prevalence of blood and prostate cancers in these regions is fueling the demand for ibrutinib.

Competitive Landscape

Key players in the ibrutinib market include Beacon Pharmaceuticals, Janssen Pharmaceuticals, Zydus Cadila, Pharmacyclics Inc., Johnson & Johnson, Incepta Pharmaceuticals, Bluepharma, AbbVie, Eli Lilly, and AstraZeneca. These companies are adopting various strategies, such as regulatory approvals and new product launches, to strengthen their market presence. For example, AbbVie Inc. received FDA approval in April 2020 for IMBRUVICA® (ibrutinib) in combination with rituximab for treating previously untreated patients with chronic lymphocytic leukemia (CLL).

Conclusion

The ibrutinib market is poised for significant growth over the next decade, driven by the increasing prevalence of blood cancers and advancements in cancer treatment. Key players in the market are actively pursuing regulatory approvals and expanding their product portfolios to capture a larger share of the growing demand. While potential side effects may pose challenges, ongoing research and development efforts are expected to drive new opportunities in the oncology space.

Browse Related Reports:   

For more information, please contact:

Next Move Strategy Consulting

E-Mail: info@nextmsc.com

Direct: +1-217-650-7991

Website: www.nextmsc.com

Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube

About Next Move Strategy Consulting:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

Back to blog